N. Singh

E-mail:
n.singh umcg.nl

Research

Publications
  1. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy

    Creutzberg, C. L., Leon-Castillo, A., de Boer, S. M., Powell, M. E., Mileshkin, L. R., Mackay, H. J., Leary, A., Nijman, H. W., Singh, N., Pollock, P., Fyles, A., Haie-Meder, C., Smit, V. T. H. B. M., Edmondson, R. J., Putter, H., Kitchener, H. C., Crosbie, E. J., de Bruyn, M., Nout, R. & Bosse, T., Oct-2019, In : Annals of Oncology. 30, p. 899-+ 2 p.

    Research output: Contribution to journalMeeting AbstractAcademic

  2. Patterns of recurrence in the randomised PORTEC-3 trial of chemoradiotherapy for endometrial cancer

    De Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., Fyles, A., Baron, M. H., Jurgenliemk-Schulz, I. M., Kitchener, H. C., Nijman, H. W., Wilson, G., Kolodziej, I., Carinelli, S., Lutgens, L. C. H. W., Smit, V. T. H. B. M., Singh, N., Nout, R. A., Verhoeven-Adema, K. W., Putter, H. & Creutzberg, C. L., Apr-2018, In : Radiotherapy and Oncology. 127, p. S171-S172 2 p.

    Research output: Contribution to journalMeeting AbstractAcademic

  3. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer

    PORTEC Study Grp, Feb-2018, In : Annals of Oncology. 29, 2, p. 424-430 7 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (4) »

View graph of relations

ID: 11179370